This research says it did. Is it because the junction point lies with exons of both genes?
-
This research says it did. Is it because the junction point lies with exons of both genes?
-
Sure, you can still pick up chromosomal and other structural rearrangements with exome sequencing, just not 100% of the time. You're correct that the reason this worked was due to the genes rearranging and effectively merging in the genome. Because of that, the capture kit still got reads that mapped to the end of one or the other of the genes (with the remainder mappable to the other gene).
This would be in contrast to detecting fusion transcripts arising from neighboring genes being coexpressed and spliced together. Those sorts of situations wouldn't be detectable with exome sequencing. -
The answer is that it depends on:
- where fusion junction point lies (it is "well" inside an exon which should be 'captured' properly and both genes involved in fusion should captured properly),
- coverage of sequencing
Whole genome sequencing and RNA-seq are ones of the most used for finding fusion genes and/or translocations.Comment
-
Hi,Originally posted by ymc View Posthttp://www.ncbi.nlm.nih.gov/pubmed/23313954
This research says it did. Is it because the junction point lies with exons of both genes?
Have you detected fusions using Exome tumor data?
Thanks,
SachinComment
-
For anyone interested: They used dRanger (not publicly available) and Breakpointer in order to detect the fusion from exome data.Comment
-
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...Today, 09:55 AM -
Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.
We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing...
Comment